WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526933

CAS#: 1181226-02-7

Description: ZL006 is a PSD95-nNOS protein-protein interaction inhibitor. ZL006 (EC50: 12.88 μM) directly inhibited binding of purified PSD95 and nNOS proteins in AlphaScreen without altering binding of PSD95 to ErbB4. ZL006 preferentially suppressed phase 2A pain behavior in the formalin test and suppressed allodynia induced by intraplantar complete Freund's adjuvant administration. Disrupting PSD95-nNOS protein-protein interactions is effective in attenuating pathological pain without producing unwanted side effects (i.e. motor ataxia) associated with NMDAR antagonists. (

Price and Availability

Size Price Shipping out time Quantity
10mg USD 150 2 Weeks
25mg USD 250 2 Weeks
50mg USD 450 2 Weeks
100mg USD 750 2 Weeks
200mg USD 1150 2 Weeks
500mg USD 1950 2 Weeks
1g USD 2850 2 Weeks
2g USD 4650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-26. Prices are subject to change without notice.

ZL006, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 526933
Name: ZL006
CAS#: 1181226-02-7
Chemical Formula: C14H11Cl2NO4
Exact Mass: 327.0065
Molecular Weight: 328.145
Elemental Analysis: C, 51.24; H, 3.38; Cl, 21.61; N, 4.27; O, 19.50

Synonym: ZL006; ZL-006; ZL 006.

IUPAC/Chemical Name: 4-(3,5-Dichloro-2-hydroxy-benzylamino)-2-hydroxybenzoic acid


InChi Code: InChI=1S/C14H11Cl2NO4/c15-8-3-7(13(19)11(16)4-8)6-17-9-1-2-10(14(20)21)12(18)5-9/h1-5,17-19H,6H2,(H,20,21)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Zhao Y, Jiang Y, Lv W, Wang Z, Lv L, Wang B, Liu X, Liu Y, Hu Q, Sun W, Xu Q, Xin H, Gu Z. Dual targeted nanocarrier for brain ischemic stroke treatment. J Control Release. 2016 Jul 10;233:64-71. doi: 10.1016/j.jconrel.2016.04.038. PubMed PMID: 27142584.

2: Chen D, Zhao T, Ni K, Dai P, Yang L, Xu Y, Li F. Metabolic investigation on ZL006 for the discovery of a potent prodrug for the treatment of cerebral ischemia. Bioorg Med Chem Lett. 2016 May 1;26(9):2152-5. doi: 10.1016/j.bmcl.2016.03.074. PubMed PMID: 27025341.

3: Smith AE, Xu Z, Lai YY, Kulkarni PM, Thakur GA, Hohmann AG, Crystal JD. Source memory in rats is impaired by an NMDA receptor antagonist but not by PSD95-nNOS protein-protein interaction inhibitors. Behav Brain Res. 2016 May 15;305:23-9. doi: 10.1016/j.bbr.2016.02.021. PubMed PMID: 26909849; PubMed Central PMCID: PMC4808404.

4: Wang Y, Zhao T, Dai P, Jiang N, Li F. Employment of Molecularly Imprinted Polymers to High-Throughput Screen nNOS-PSD-95 Interruptions: Structure and Dynamics Investigations on Monomer-Template Complexation. Chemphyschem. 2016 Mar 16;17(6):893-901. doi: 10.1002/cphc.201500941. PubMed PMID: 26728445.

5: Wang Z, Zhao Y, Jiang Y, Lv W, Wu L, Wang B, Lv L, Xu Q, Xin H. Enhanced anti-ischemic stroke of ZL006 by T7-conjugated PEGylated liposomes drug delivery system. Sci Rep. 2015 Jul 29;5:12651. doi: 10.1038/srep12651. PubMed PMID: 26219474; PubMed Central PMCID: PMC4518266.

6: Bach A, Pedersen SW, Dorr LA, Vallon G, Ripoche I, Ducki S, Lian LY. Biochemical investigations of the mechanism of action of small molecules ZL006 and IC87201 as potential inhibitors of the nNOS-PDZ/PSD-95-PDZ interactions. Sci Rep. 2015 Jul 16;5:12157. doi: 10.1038/srep12157. PubMed PMID: 26177569; PubMed Central PMCID: PMC4503980.

7: Lee WH, Xu Z, Ashpole NM, Hudmon A, Kulkarni PM, Thakur GA, Lai YY, Hohmann AG. Small molecule inhibitors of PSD95-nNOS protein-protein interactions as novel analgesics. Neuropharmacology. 2015 Oct;97:464-75. doi: 10.1016/j.neuropharm.2015.05.038. PubMed PMID: 26071110; PubMed Central PMCID: PMC4539046.

8: Hu W, Guan LS, Dang XB, Ren PY, Zhang YL. Small-molecule inhibitors at the PSD-95/nNOS interface attenuate MPP+-induced neuronal injury through Sirt3 mediated inhibition of mitochondrial dysfunction. Neurochem Int. 2014 Dec;79:57-64. doi: 10.1016/j.neuint.2014.10.005. PubMed PMID: 25452082.

9: Doucet MV, Levine H, Dev KK, Harkin A. Small-molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice. Neuropsychopharmacology. 2013 Jul;38(8):1575-84. doi: 10.1038/npp.2013.57. PubMed PMID: 23446451; PubMed Central PMCID: PMC3682152.

10: Zhou L, Li F, Xu HB, Luo CX, Wu HY, Zhu MM, Lu W, Ji X, Zhou QG, Zhu DY. Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat Med. 2010 Dec;16(12):1439-43. doi: 10.1038/nm.2245. Erratum in: Nat Med. 2011 Sep;17(9):1153. PubMed PMID: 21102461.